Celularity Inc (CELU)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Celularity Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 290.6% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.46 | – | 18 | 378.90 | -73.30 | 2 | 2 |
| 2025: Q1 | -0.46 | – | 18 | 23.50 | -73.30 | 2 | 2 |
| 2025: Q2 | -0.85 | -356.90 | 6 | -52.60 | -427.50 | -1 | -1 |
| 2025: Q3 | -0.80 | – | 5 | -43.20 | -436.70 | -4 | -4 |
| 2025: Q4 | -0.84 | – | 4 | -77.40 | -593.60 | -5 | -5 |
| 2026: Q1 | -0.84 | – | 4 | -77.40 | -593.60 | -5 | -5 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Celularity Inc., ein Unternehmen für Zell- und regenerative Medizin, konzentriert sich auf die Behandlung altersbedingter Erkrankungen mit neuartigen Therapien.
| Employees | 115 |
|---|---|
| Headquarters | Florham Park, NJ |
| Website | celularity.com |
| IPO Date | 8. Aug 2019 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert Joseph Hariri M.D., Ph.D. | Founder, CEO & Chairman | 1959 |
| John Sprague | Acting Chief Financial Officer | – |
| Steven N. Gordon Esq. | Chief Operating and Administrative Officer & Director | – |
| Carlos Ramirez | SVP of Investor Relations | – |
| Kyle Harold Fletcher Esq. | Chief Legal and Strategy Officer & Corporate Secretary | 1985 |
| Sharmila Koppisetti M.D. | Senior Vice President of Clinical Dev. Immunology & Drug Safety | – |
| Tim Wilk | Senior Vice President of Technical Operations | – |
| Ricardo J. Gonzalez | Chief Commercial Officer | 1971 |
| David Jakob Lemus CPA, M.S., MBA | Treasurer | 1962 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.